FTSE 250 pharmaceutical group HIkma is to buy the Egyptian Company for Pharmaceuticals & Chemical Industries as it strengthens its position in a rapidly growing market.
It is to pay EGP142.4m - around $22.2m - to buy the firm from a consortium of shareholders.
Hikma's Chief Executive, Said Darwazah, said that since his company entered the Egyptian market in 2007, it had rapidly grown its presence in a country that had excellent growth opportunities.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This acquisition will further accelerate that growth, expanding our product portfolio and adding additional manufacturing capacity and technologies," he said.
The company quoted IMS Health figures, which showed Egypts private retail market was valued at around $2.3bn and grew by 10.6% in the twelve months to June 2012.
Hikma Egypt said it was the seventeenth largest pharmaceutical manufacturer in Egypt, with an estimated market share of 1.6%.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the USMedium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.
